APA (7th ed.) Citation

CM, S., B, W., K, E., H, K., C, M., SW, E., . . . RB, L. (2026). Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts. HemaSphere, 10(7), e70438. https://doi.org/10.1002/hem3.70438

Chicago Style (17th ed.) Citation

CM, Smith, et al. "Preclinical Evaluation of the ROR1-targeting Antibody-drug Conjugates Zilovertamab Vedotin and VLS-211 Against B-cell ALL Patient-derived Xenografts." HemaSphere 10, no. 7 (2026): e70438. https://doi.org/10.1002/hem3.70438.

MLA (9th ed.) Citation

CM, Smith, et al. "Preclinical Evaluation of the ROR1-targeting Antibody-drug Conjugates Zilovertamab Vedotin and VLS-211 Against B-cell ALL Patient-derived Xenografts." HemaSphere, vol. 10, no. 7, 2026, p. e70438, https://doi.org/10.1002/hem3.70438.